Tinland A, Zemmour K, Auquier P, Boucekine M, Girard V, Loubière S, Fond G, Boyer Laurent
EA 3279 - Public Health, Chronic Diseases and Quality of Life - Research Unit, Aix-Marseille University, 13005, Marseille, France.
Department of Psychiatry, Sainte-Marguerite University Hospital, Marseille, France.
Soc Psychiatry Psychiatr Epidemiol. 2017 Sep;52(9):1113-1122. doi: 10.1007/s00127-017-1411-z. Epub 2017 Jun 27.
The aim of this study was to investigate the factors associated with non-adherence to medication in a large multi-center sample of homeless schizophrenia (HSZ) patients.
This multi-center study was conducted in four French cities: Lille, Marseille, Paris, and Toulouse. In addition to the Medication Adherence Rating Scale (MARS), sociodemographic information, history of homelessness, illness severity using the Modified Colorado Symptom Index (MCSI) and the Multnomah Community Integration Scale (MCAS), and drug information were collected.
In total, 218 HSZ patients (16.1% women, mean age 36.8 ± 9.3 years) were included in this study. In the multivariate analysis, being a woman and having higher illness severity (MCSI score) and lower "acceptance of illness" (MCAS score) were significantly associated with lower MARS index scores. Compared to men, women had lower MARS dimension 1 ('medication adherence behavior') and dimension 3 ('negative side effects and attitudes toward psychotropic medication') scores. First-generation antipsychotic use was also associated with lower MARS dimension 3 scores.
HSZ women reported lower adherence than men, mainly due to having more subjective negative side effects and worse attitudes toward psychotropic medication. Future longitudinal studies should confirm these findings and explore the applicability of specific pharmacological and non-pharmacological treatment strategies for HSZ women, including treatment dose adaptation and psychoeducation. Clinical trial number NCT01570712.
本研究旨在调查大量多中心无家可归精神分裂症(HSZ)患者中与药物治疗不依从相关的因素。
这项多中心研究在法国的四个城市进行:里尔、马赛、巴黎和图卢兹。除了药物依从性评定量表(MARS)外,还收集了社会人口学信息、无家可归病史、使用改良科罗拉多症状指数(MCSI)和摩特诺玛社区融入量表(MCAS)评估的疾病严重程度以及药物信息。
本研究共纳入218例HSZ患者(女性占16.1%,平均年龄36.8±9.3岁)。在多变量分析中,女性、疾病严重程度较高(MCSI评分)以及“对疾病的接受度”较低(MCAS评分)与较低的MARS指数评分显著相关。与男性相比,女性的MARS维度1(“药物治疗依从行为”)和维度3(“负面副作用及对精神药物的态度”)得分较低。使用第一代抗精神病药物也与较低的MARS维度3得分相关。
HSZ女性的依从性低于男性,主要是因为有更多主观负面副作用以及对精神药物的态度较差。未来的纵向研究应证实这些发现,并探索针对HSZ女性的特定药物和非药物治疗策略的适用性,包括调整治疗剂量和进行心理教育。临床试验编号NCT01570712。